Medicine and Dentistry
Biochemical Recurrence
7%
Biopsy Technique
8%
Bladder
17%
Bladder Cancer
50%
Carbon 11
9%
Castration Resistant Prostate Cancer
6%
Chemotherapy
21%
Choline
8%
Clear Cell Renal Cell Carcinoma
7%
Clinical Trial
6%
Computer Assisted Tomography
9%
Cystectomy
37%
Diagnosis
9%
Disease
20%
Family History
8%
Gallium 68
14%
Immunotherapy
12%
Kidney Metastasis
9%
Lymph Node
30%
Lymph Node Metastasis
13%
Magnetic Resonance Imaging
8%
Malignant Neoplasm
17%
Metastatic Carcinoma
15%
Muscle Invasive Bladder Cancer
9%
Neobladder
10%
Neoplasm
31%
Oncology
7%
Overall Survival
9%
Pelvis
13%
Polyethylene Terephthalate
12%
Positron Emission Tomography
16%
Positron Emission Tomography-Computed Tomography
12%
Prostate Cancer
100%
Prostate Specific Antigen
14%
Prostate Specific Membrane Antigen
20%
Prostatectomy
39%
Quality of Life
6%
Radiation Therapy
15%
Radiosurgery
8%
Recurrent Disease
15%
Retroperitoneal Lymph Node Dissection
19%
Sunitinib
6%
Surgery
15%
Survival Rate
6%
Systemic Therapy
11%
Transitional Cell Carcinoma
26%
Urinary Diversion
6%
Urologist
7%
Urology
8%
Urothelial Cancer
11%
Keyphrases
Apoptosis
6%
Biochemical Recurrence
7%
Biochemical Recurrence-free Survival
7%
Bladder Cancer
45%
Bone Metastasis
7%
Cancer Patients
10%
Castration-resistant Prostate Cancer
7%
Chemotherapy
14%
Confidence Interval
9%
Cystectomy
11%
Docetaxel
9%
Everolimus
9%
Family History
8%
Germany
14%
High Risk
9%
Invasive Urothelial Carcinoma
7%
Lymph Node
13%
Lymph Node Metastasis
14%
Metastasis
8%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
21%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
7%
Metastatic Renal Cell Carcinoma (mRCC)
20%
Muscle-invasive Bladder Cancer
9%
Nivolumab
7%
Overall Survival
15%
Pazopanib
8%
Phase II Trial
7%
Positron Emission Tomography
10%
Prednisone
7%
Progression-free Survival
6%
Prostate
8%
Prostate Cancer
62%
Prostate Cancer Patients
18%
Prostate Cancer Survivors
6%
Prostate-specific Antigen
34%
Radical Cystectomy
30%
Radical Prostatectomy
39%
Radioguided Surgery
8%
Recurrent Prostate Cancer
13%
Renal Cell Carcinoma
10%
Salvage Radiotherapy
6%
Sunitinib
11%
Systemic Therapy
8%
Tumor
18%
Upper Tract Urothelial Carcinoma
10%
Urinary Diversion
6%
Urologists
7%
Urology
8%
Urothelial Cancer
9%
Urothelial Carcinoma
7%